Trade

with

Genomic Health Inc
(NASDAQ: GHDX)
AdChoices
33.76
+1.00
+3.05%
After Hours :
33.76
0.00
0.00%

Open

32.94

Previous Close

32.76

Volume (Avg)

146.96k (149.83k)

Day's Range

32.57-33.98

52Wk Range

23.90-37.24

Market Cap.

1.03B

Dividend Rate ( Yield )

-

Beta

0.60

Shares Outstanding

31.53M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Diagnostics & Research
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 261.60M

    • Net Income

    • -12.76M

    • Market Cap.

    • 1.03B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -7.69

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.60

    • Forward P/E

    • -64.94

    • Price/Sales

    • 3.84

    • Price/Book Value

    • 7.42

    • Price/Cash flow

    • 163.93

      • EBITDA

      • -5.51M

      • Return on Capital %

      • -12.12

      • Return on Equity %

      • -14.83

      • Return on Assets %

      • -12.12

      • Book Value/Share

      • 4.55

      • Shares Outstanding

      • 31.53M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/20/2014
      Hold
        • 1 Year Price Target

        • 27.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.52

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 10.70

          • 21.91

          • Net Income

            YTD/YTD (last year)

          • -

          • -5.55

          • Net Income

            Q/Q (last year)

          • -

          • 0.44

          • Sales (Revenue)

            5-Year Annual Average

          • 18.79

          • 47.82

          • Net Income

            5-Year Annual Average

          • -

          • 4.98

          • Dividends

            5-Year Annual Average

          • -

          • 5.31

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 83.16

            • 42.70

            • Pre-Tax Margin

            • -7.54

            • 11.63

            • Net Profit Margin

            • -7.69

            • 9.55

            • Average Gross Margin

              5-Year Annual Average

            • 82.10

            • 43.76

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -0.10

            • 11.34

            • Average Net Profit Margin

              5-Year Annual Average

            • -0.30

            • 52.13B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.62

              • Current Ratio

              • 4.52

              • 1.23

              • Quick Ratio

              • 4.24

              • 0.76

              • Interest Coverage

              • -

              • 5.98

              • Leverage Ratio

              • 1.24

              • 2.16

              • Book Value/Share

              • 4.55

              • 14.94

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -46.73

                • 32.47

                • P/E Ratio 5-Year High

                • -57.64

                • 325.07

                • P/E Ratio 5-Year Low

                • -17.65

                • 154.73

                • Price/Sales Ratio

                • 3.60

                • 2.26

                • Price/Book Value

                • 6.95

                • 2.95

                • Price/Cash Flow Ratio

                • 163.93

                • 18.55

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -14.83

                    (-0.60)

                  • 9.34

                    (9.80)

                  • Return on Assets %

                    (5-Year Average)

                  • -12.12

                    (-0.50)

                  • 4.63

                    (5.44)

                  • Return on Capital %

                    (5-Year Average)

                  • -14.83

                    (-0.60)

                  • 5.73

                    (6.77)

                  • Income/Employee

                  • -

                  • 17.17k

                  • Inventory Turnover

                  • -

                  • 5.07

                  • Asset Turnover

                  • 1.58

                  • 0.48

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -11.83M
                  Operating Margin
                  -4.52
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  163.93
                  Ownership

                  Institutional Ownership

                  91.24%

                  Top 10 Institutions

                  75.20%

                  Mutual Fund Ownership

                  28.78%

                  Float

                  53.41%

                  5% / Insider Ownership

                  5.83%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Champlain - Small Cap Equity

                  •  

                    1,173,590

                  • 0.96

                  • 3.76

                  • Scottish Mortgage Inv Tr

                  •  

                    571,920

                  • 0.00

                  • 1.81

                  • Fidelity® Select Health Care Portfolio

                  •  

                    530,000

                  • 0.00

                  • 1.68

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    516,228

                  • 0.00

                  • 1.64

                  • Champlain Small Company Fund

                  •  

                    425,000

                  • 6.25

                  • 1.35

                  • iShares Nasdaq Biotechnology

                  •  

                    418,547

                  • -0.69

                  • 1.54

                  • SPDR® S&P Biotech ETF

                  •  

                    393,841

                  • 3.60

                  • 1.45

                  • Old Westbury Small & Mid Cap Fund

                  •  

                    275,000

                  • 0.00

                  • 0.87

                  • iShares Russell 2000 (AU)

                  •  

                    257,732

                  • -1.01

                  • 0.95

                  • Vanguard Small Cap Index

                  •  

                    246,503

                  • 0.76

                  • 0.78

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Baker Bros Advisors LLC

                  •  

                    13,654,902

                  • +0.01%

                  • 43.71

                  • Fidelity Management and Research Company

                  •  

                    1,725,348

                  • -32.93%

                  • 5.52

                  • Camber Capital Management LLC

                  •  

                    1,725,000

                  • +130.00%

                  • 5.52

                  • Baillie Gifford & Co Limited.

                  •  

                    1,394,108

                  • +4.22%

                  • 4.46

                  • Champlain Investment Partners, LLC

                  •  

                    1,262,090

                  • +0.89%

                  • 4.04

                  • Vanguard Group, Inc.

                  •  

                    952,757

                  • -0.03%

                  • 3.05

                  • TPG Capital, L.P.

                  •  

                    910,273

                  • 0.00%

                  • 2.91

                  • BlackRock Fund Advisors

                  •  

                    738,214

                  • -7.24%

                  • 2.36

                  • State Street Corp

                  •  

                    668,085

                  • -24.34%

                  • 2.14

                  • IronBridge Capital Management, LLC

                  •  

                    465,740

                  • -19.62%

                  • 1.49

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Diagnostics & Research

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Genomic Health Inc was incorporated in Delaware in August 2000. It is a healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company is engaged in the development and commerci...morealization of genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The Company's Oncotype DX breast and colon tests have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company provides its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provide physic...moreians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ, or DCIS and a Genomic Prostate Score, or GPS, for prostate cancer. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, or RT-PCR, in standard tumor pathology specimens to provide tumor-specific information, or the "oncotype" of a tumor. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and its Oncotype DX colon cancer test analyzes the expression levels of 12 genes. Its Oncotype DX prostate cancer test measures the level of expression of 17 genes across four biological pathways to predict prostate cancer aggressiveness in men with low risk disease. It has a direct commercial presence with employees and consultants in the United States and certain other countries, and its Oncotype DX breast and colon cancer tests are also available outside of the United States through a network of distributors. The Company faces competition from companies that offer products or have conducted research to profile genes, gene expression or protein expression in breast, colon or prostate cancer, including public companies such as, GE Healthcare, a business unit of General Electric Company, Hologic, Inc., Myriad Genetics, Inc., NanoString Technologies, Inc., Novartis AG, Qiagen N.V. and Response Genetics, Inc., and many private companies. It faces competition from commercial laboratories with distribution networks for diagnostic tests, such as Laboratory Corporation of America Holdings and Quest Diagnostics Incorporated. The Company holds 32 issued patents in the United States and 65 issued patents outside of the United States. As a clinical reference laboratory, the Company is subject to hold certain federal, state and local licenses, certifications and permits to conduct its business.lessless

                  Key People

                  Kimberly J. Popovits

                  CEO/Chairman of the Board/Director/President

                  G. Bradley Cole

                  CFO/Chief Accounting Officer/COO/Secretary

                  Steven Shak,M.D.

                  Executive VP, Divisional

                  Dr. Fred E. Cohen,M.D.,D.Phil.

                  Director

                  Dr. Henry J. Fuchs,M.D.

                  Director

                  • Genomic Health Inc

                  • 301 Penobscot Drive

                  • Redwood City, CA 94063

                  • USA.Map

                  • Phone: +1 650 556-9300

                  • Fax: -

                  • genomichealth.com

                  Incorporated

                  2000

                  Employees

                  684

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: